Understand the source comparison
Comparison: Research Peptides for Gastric Ulcer Models
BPC-157 VEGFR2 upregulation → angiogenesis, mucosal blood flow restoration Ethanol-induced, ischemia-reperfusion injury 10–50 mcg/kg IP or oral daily for 7–14 days Minimal effect in NSAID models where vascular injury is secondary Gold standard for vascular-com
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGFR2 upregulation → angiogenesis, mucosal blood flow restoration
- Ethanol-induced, ischemia-reperfusion injury
- 10–50 mcg/kg IP or oral daily for 7–14 days
- Minimal effect in NSAID models where vascular injury is secondary
- Gold standard for vascular-component ulcers; weakest in prostaglandin-deficient models
- KPV
- NF-kB inhibition → reduced TNF-alpha/IL-6, improved tight junction integrity
- NSAID-induced, colitis, inflammatory bowel disease models
- 1–5 mg/kg oral or IP daily for 5–10 days
- No direct angiogenic effect; requires intact vasculature to work
- Best choice for inflammation-driven ulcers; does not address ischemia
- TB-500
- Actin sequestration → fibroblast migration, collagen deposition, ECM remodeling
- Stress-induced, chronic ulcers with fibrotic component
- 0.5–2 mg/kg SC twice weekly for 2–4 weeks
- Slowest onset. Structural repair takes longer than vascular or inflammatory modulation
- Ideal for chronic or recurrent ulcers requiring architectural repair; often paired with BPC-157